Resveratrol
Of 1,638 on-market resveratrol products in the January 2026 DSLD dump, the median declared dose is 40 mg, and 40.3% list Polygonum cuspidatum (Japanese knotweed) root extract-sourced resveratrol as the primary form.
Form share
Of 1,590 products with an identifiable primary form, here is the share held by each form of Resveratrol on the market today.
Embed this chart
Free to embed on your site or article — attribution and a link back are built into the frame.
| Form | Quality tier | n | Share |
|---|---|---|---|
| Polygonum cuspidatum (Japanese knotweed) root extract-sourced resveratrol | Unrated | 640 | 40.3% |
| Trans-Resveratrol | Unrated | 637 | 40.1% |
| unspecified/undisclosed form | Unrated | 313 | 19.7% |
Form share over time
Entry-year breakdown of the top forms, 2012–2025.
Dose distribution
Deciles of declared dose per serving (mg), among 1,003 products with a disclosed amount.
Embed this chart
Free to embed on your site or article — attribution and a link back are built into the frame.
- 25.1% of products fall below the fairy-dust threshold (20 mg, 20% of the studied low dose).
- 32.1% of products don't disclose an amount because Resveratrol is declared inside a proprietary blend.
Where does your dose rank?
Enter a per-serving dose (mg) to see exactly how it compares to the 1,003 on-market resveratrol products with a disclosed amount. The chart above groups doses into deciles; this looks up the exact percentile for one number.
By dosage form
By target group
Top brands
Search interest over time
How often people search for resveratrol on Google, US only, the last 5 years. This is public interest, not DSLD label data — a spike here doesn't necessarily line up with anything on this page, and Google's own index (100 = that term's peak popularity in the chosen window) is relative, not an absolute search-volume count.
Or see this search directly on trends.google.com.
Forms explained
Label discloses only "Resveratrol" with no isomer or source declaration.
The biologically relevant isomer and what most products declare, but the human trials verified here report "resveratrol" without isomer detail in the abstract, and trans vs unspecified was not compared; not ranked. Human exposure to free resveratrol is low relative to its glucuronide/sulfate conjugates (up to ~20-fold higher AUC for metabolites at 0.5-5 g/day).
Source: Brown VA et al. 2010, Cancer Res 70(22):9003-9011, PMID 20935227
Typical standardization: Varies; labels cite 10-99% resveratrol (e.g. 20%, 50%, 99%)
Botanical-source descriptor (the dominant commercial source -- several hundred on-market rows name it in raw_form) rather than a distinct delivery form; standardization varies widely and no human comparison against synthetic/fermented resveratrol was verified, so it is not ranked. A row whose own name is the plant source (e.g. "Japanese Knotweed Root Extract") declares extract mass, not resveratrol, and is kept unresolved; a "Resveratrol" row that merely lists the plant in raw_form keeps its declared mg.
Reference values
- RDA (adult): not established — Plant polyphenol (stilbene), not an essential nutrient; no DRI exists.
- Tolerable Upper Intake Level (adult): not established — Not established -- no IOM/NASEM UL exists. In a repeat-dose study (n=40 healthy volunteers, 0.5/1.0/2.5/5.0 g daily x29 days) resveratrol was judged safe but the 2.5 and 5 g doses caused mild-to-moderate GI symptoms (Brown VA et al. 2010, Cancer Res 70(22):9003-9011, PMID 20935227). In a 52-week Alzheimer trial (500 mg/day escalating to 1,000 mg twice daily) nausea, diarrhea and weight loss were the most common adverse events (PMID 26362286). Tolerability observations, not a UL.
- Studied clinical dose range: 100–2000 mg
- Zhu X et al. 2017, Nutr Metab (Lond) 14:60, PMID 29018489 -- meta-analysis, 9 RCTs/283 participants with type 2 diabetes; fasting glucose and insulin improved, with a larger glucose effect at >=100 mg/day than <100 mg/day. Liu Y et al. 2015, Clin Nutr 34(1):27-34, PMID 24731650 -- meta-analysis, 6 RCTs/247 subjects; overall no significant BP effect, but >=150 mg/day lowered systolic BP by 11.9 mmHg. Upper bound: Turner RS et al. 2015, Neurology 85(16):1383-1391, PMID 26362286 -- RCT, n=119 mild-moderate Alzheimer disease, 500 mg/day escalating to 1,000 mg twice daily x52 weeks; safety/biomarker primary outcomes -- well tolerated, CSF and plasma Abeta40 declined less than on placebo and brain-volume loss was greater with resveratrol (authors: "alters some AD biomarker trajectories"). 2,000 mg/day is the maximum exposure in that trial, not an efficacy threshold.
- Note: Most labels declare "Resveratrol" or "Trans-Resveratrol" with the plant source (Polygonum cuspidatum / Japanese knotweed root, occasionally grape) in raw_form and a % standardization in the notes. Rows named "Japanese Knotweed Root Extract" or "Polygonum cuspidatum" declare extract mass, not resveratrol: they are not compound aliases but are listed as aliases of the knotweed form, so they match with the amount left unresolved. The separate stilbene pterostilbene ("Pterostilbene", "Trans-Pterostilbene") is a different compound and is not aliased. The efficacy signal in the meta-analyses is modest and dose-dependent; the 100-150 mg/day thresholds are subgroup findings.